OCUL vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. OCUL and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined OCUL and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Its only approved, revenue-generating product is DEXTENZA, a dexamethasone insert placed in the tear duct to treat inflammation and pain after eye surgery and, more recently, allergic eye itching. DEXTENZA generates modest, roughly flat sales, so the company is effectively pre-profit and funds itself with a large cash balance while it invests heavily in clinical development.

Full OCUL guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• OCUL drivers: AXPAXLI in wet AMD; Expanding Phase 3 pipeline.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick OCUL if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the OCUL and REGN guides.

OCUL. Ocular is effectively a pre-profit biotech: DEXTENZA sales were roughly flat and small while R&D spending rose to fund several Phase 3 trials, widening the net loss. The market capitalization of around $1.8 billion is many times trailing revenue because investors are pricing the potential of AXPAXLI rather than current earnings, which is typical for a clinical-stage biotech with a de-risked lead asset.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, MAY 2026): OCUL shows revenue (fy2025) ~$52 million, revenue (q1 2026) ~$10.8 million, net loss (q1 2026) ~-$88.6 million, r&d expense (q1 2026) ~$66.2 million; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

OCUL and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined OCUL and REGN exposure against your real portfolio. It is not an investment adviser.